A guide to biopharma solutions from Oxford Nanopore — from discovery to development
)
- Published on:
)
Developing a new drug is a lengthy, high-risk endeavour. At every stage, researchers and manufacturers rely on genomic data for decision-making, whether to identify biomarkers, validate plasmid constructs, verify integration into production cell lines, demonstrate viral vector or mRNA therapeutic integrity, monitor manufacturing processes, or confirm product quality before release. Yet the analytical methods traditionally used to provide that data are fragmented and incomplete.
This guide introduces Oxford Nanopore sequencing solutions that can be applied from biomarker discovery through to final product quality control (QC) testing, consolidating multiple legacy assays with one platform and enabling faster, more confident decision-making.
In this getting started guide, you will:
- Find out how Oxford Nanopore sequencing delivers multiomic insight with a single sequencing platform
- Discover end-to-end workflows tailored for biopharma applications, such as amplicon analysis, plasmid construct verification, viral vector characterisation, and mRNA therapeutic quality control
- Learn about the range of Oxford Nanopore devices
- Read real-world case studies of how nanopore sequencing is being used to address needs in the drug development pipeline
